Skip to main content Accessibility help
×
Home
  • Access
  • Print publication year: 2015
  • Online publication date: April 2015

43 - Acute viral hepatitis

from Part VII - Clinical syndromes: gastrointestinal tract, liver, and abdomen
    • Send chapter to Kindle

      To send this chapter to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Available formats
      ×

      Send chapter to Dropbox

      To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

      Available formats
      ×

      Send chapter to Google Drive

      To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

      Available formats
      ×

Summary

Acute viral hepatitis is a systemic infection with predominant hepatic involvement and remains a significant cause of morbidity and mortality in the United States despite the availability of effective vaccines against the two major causes of acute viral hepatitis, namely A and B. There are five major hepatotropic viruses (A, B, C, D, and E) that cause acute hepatitis with acute hepatic inflammation and necrosis. Acute viral hepatitis typically runs its course in 6 months or less, in contrast to chronic hepatitis, which persists for longer. However, with modern serologic and molecular diagnostic testing, the time course is less important in distinguishing acute from chronic viral hepatitis. The clinical illness produced by these viruses can range from asymptomatic or clinically inapparent to a fulminant and fatal acute infection. A major distinction between hepatitis A and hepatitis B, C, D, and E is that the former causes acute hepatitis only, in contrast to the latter four which cause acute and chronic hepatitis. Other viral infections, such as herpes simplex, Epstein–Barr virus (EBV), cytomegalovirus (CMV), and parvovirus B19, can present with prominent hepatic dysfunction, although they are usually multisystem disorders. Hepatitis G, human herpesviruses, adenovirus, coronavirus, and TT virus (TTV) have also been implicated in causing hepatic dysfunction, but their clinical significance remains dubious.

Hepatitis A virus

The hepatitis A virus (HAV) is an RNA virus, identified in 1973, transmitted via the fecal–oral route and is a common cause of acute viral hepatitis in North America. Community outbreaks due to contaminated water or food are well recognized. Inhabitants in low-socioeconomic areas, international travelers, intravenous drug users, and homosexual men are at particular risk of HAV infection. In the United States, the incidence has decreased remarkably since the introduction (1995) of HAV vaccination and its administration to all children as part of the universal childhood vaccination policy since 2006. In underdeveloped countries, HAV infection typically occurs in childhood and is subclinical (age ≤6 years, 70% are asymptomatic), with most of the population infected before adulthood acquiring life-long immunity. HAV infection occurring in older children and adults is more likely to be symptomatic, with increased morbidity and even mortality (Figure 43.1).

Related content

Powered by UNSILO
Suggested reading
Bhamidimarri, KR, Park, J, Dieterich, D.Management of hepatitis B virus coinfection: HIV, hepatitis C virus, hepatitis D virus. Curr Hepatitis Rep. 2011;10(4):262–268.
Bhattarai, N, Stapleton, JT. GB virus C: the good boy virus?Trends Microbiol. 2012;20(3):124–130.
Deterding, K, Grüner, N, Buggish, P, et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis. 2013;13(6):497–506.
Hajarizadeh, B, Grebely, J, Dore, GJ. Epidemiology and natural history of HCV infection. NatRev Gastroenterol Hepatol. 2013;10(9):553–562.
Jeong, SH, Lee, HS. Hepatitis A: clinical manifestations and management. Intervirology. 2010;53(1):15–19.
Jindal, A, Kumar, M, Sarin, SK. Management of acute hepatitis B and reactivation of hepatitis B. Liver Int. 2013;33(Suppl 1):164–175.
Jung, YM, Park, SJ, Kim, JS, et al. Atypical manifestations of hepatitis A infection: a prospective, multicenter study in Korea. J Med Virol. 2010;82(8):1318–1326.
Norvell, JP, Blei, AT, Jovanovic, BD, Levitsky, J. Herpes simplex virus hepatitis: an analysis of the published literature and institutional cases. Liver Transpl. 2007;13(10):1428–1434.
Smedile, A, Rizzetto, M. HDV: thirty years later. Dig Liver Dis. 2011;43(Suppl 1):S15–S18.
Young, NS, Brown, KE. Parvovirus B19. N Engl J Med. 2004;350(6):586–597.